Bausch Health Companies Inc
Here’s whether Bausch Health Companies Inc (BHC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 47 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-1.10% over 10 days); rising volume on a downtrend (distribution, 1.36x avg). Currently 35.0% off its 52-week high. Score: -1/7.
BHC is trading below its 200-day MA ($6.37) — a key warning sign the longer-term trend is under pressure. An RSI of 47.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +6.6% compares to +27.9% for SPY (trailed the market by 21.3%). The current 35.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.